Sanguine is a leader in custom specimen procurement used by biopharmaceutical companies to accelerate precision medicine

BroadOak invested in CDI Labs, a provider of serological biomarker discovery services and monoclonal antibody manufacturing

BroadOak portfolio company PBS Biotech, an innovative manufacturer of single-use bioreactors, has completed a $22 million

BroadOak portfolio company PhenoVista Biosciences, a leading provider of both custom and off-the-shelf imaging-based assay services,

BioCare Medical, a leading provider of innovative, automated immunohistochemistry (IHC) and FISH (Fluorescent in situ hybridization)

BroadOak partnered with United BioChannels (UBC) to acquire ORFLO Technologies (ORFLO) in October 2022. ORFLO, a

Flagship Biosciences hired industry veteran Tom Turi as Chief Scientific Officer. Tom will help grow the

BroadOak completed a growth equity investment in EmVenio Research, alongside members of the company’s management team

Following BroadOak’s growth equity investment in Flagship Biosciences, Flagship Biosciences has acquired Interpace Pharma Solutions, a